socalTECH

JUNE 11, 2015

San Diego-based RNA therapeutics developer Arcturus Therapeutics announced this morning that it is in a strategic collaboration deal, with Johnson & Johnson Innovation. Plus, Janssen will assume responsibility for development and commercialization costs associated with the new program.

Arcturus 100

Arcturus San Diego Sales Platform 100

socalTECH

MAY 16, 2011

Pasadena-based venture capital firm Arcturus Capital has scored an exit out of its portfolio this morning, as Milpitas, California-based Pliant Technology was acquired by SanDisk in a deal worth $327M. Arcturus first invested in Pliant in 2007. SanDisk is a major manufacturer of flash memory.

Arcturus 150

Arcturus Pasadena Venture Capital Equity 150

Xconomy

FEBRUARY 2, 2018

Arcturus Therapeutics (NASDAQ: ARCT ) said today it has fired co-founder and CEO Joseph E. The unexpected announcement nevertheless sent the price of Arcturus shares spiraling in after-hours trading, falling by $1.38, nearly 19 percent, to. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Arcturus 56

Arcturus San Diego Pricing Report 56

Xconomy

MAY 30, 2018

The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT ) named four new board members Tuesday, after the four directors who fired founding CEO Joseph Payne resigned as part of a settlement agreement that was approved Monday by an Israeli court. No financial terms were disclosed.

Arcturus 56

Arcturus San Diego Develop Development 56

Xconomy

OCTOBER 23, 2017

Things have been moving quickly in recent weeks for the San Diego RNA drug developer Arcturus Therapeutics. After initiating a reverse merger last month, Arcturus signed a research collaboration and worldwide licensing agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson (NYSE: JNJ ) family of companies.

Arcturus 65

Arcturus San Diego Research Develop 65

Xconomy

MAY 30, 2017

San Diego-based Arcturus Therapeutics said today Cystic Fibrosis Foundation Therapeutics has agreed to provide $3 million to fund research and development of a new messenger RNA drug that could be broadly used to treat cystic fibrosis patients. Arcturus says its technology can be used to make.

Arcturus 65

Arcturus San Diego Research Funding 65

Xconomy

MAY 3, 2018

In the five years since it was founded, San Diego-based Arcturus Therapeutics (NASDAQ: ARCT ) says it has built a versatile platform for developing a variety of RNA-based medicines. Dueling lawsuits between the ousted CEO and the board could consume. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Arcturus 49

Arcturus Develop Development San Diego 49

Xconomy

FEBRUARY 27, 2018

The schism between Arcturus Therapeutics’ board and its former chief executive is now putting the company at risk of missing key financial reporting deadlines, and possibly even losing its stock listing. Arcturus (NASDAQ: ARCT ) blamed the failure on Joseph Payne, who was fired as CEO on Feb. Arcturus says Payne and others.

Arcturus 49

Arcturus San Diego Report Develop 49

Xconomy

MAY 31, 2018

The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT ) on Thursday reinstated fired CEO Joseph Payne and named ResMed (NYSE: RMD ) founder Peter Farrell as chairman of the company’s new board of directors. He co-founded Arcturus and is the company’s largest shareholder, with a 13.7 percent stake.

Arcturus 49

Arcturus San Diego Develop Development 49

Xconomy

APRIL 5, 2018

As a showdown stockholders meeting draws near for San Diego’s Arcturus Therapeutics (NASDAQ: ARCT ), a proxy battle is boiling down to an argument over who represents the best interests of shareholders in the tiny RNA drug company. In an April 3 letter addressed to the company’s four board members, Arcturus co-founder and ex-CEO Joseph E.

Arcturus 49

Arcturus San Diego Company Companies 49

Xconomy

MARCH 29, 2018

The board that fired Arcturus Therapeutics co-founder and CEO Joseph E. In a lawsuit filed Tuesday (see below) and in an open letter to shareholders issued Wednesday , the Arcturus (NASDAQ: ARCT ) board ­says a pattern of alleged misconduct, deceit, and failed leadership by Payne led to his termination on January 25. Payne, who.

Arcturus 49

Arcturus San Diego Develop Development 49

Xconomy

MAY 22, 2018

After postponing a May 7 shareholder vote in a power struggle for control of San Diego’s Arcturus Therapeutics (NASDAQ: ARCT ), the company’s board of directors has set a new date for its showdown with ousted CEO Joseph Payne. In a statement Monday, Arcturus said it has rescheduled its special shareholder meeting for 10 a.m.

Arcturus 40

Arcturus San Diego Blogging Startup 40

socalTECH

MAY 16, 2014

TrueCar is venture backed by backed by USAA, Capricorn Investment Group, Upfront Ventures, Anthem Ventures, Vulcan Capital Growth Equity, Peppy Capital Partners, Arcturus Venture Capital, along with others. TrueCar is trading on the NASDAQ Global Select Market as TRUE. READ MORE>>. truecar true buying service scott painter'

Truecar 147

Truecar Pricing Arcturus Anthem 147

socalTECH

AUGUST 10, 2012

Prolacta is venture backed by such companies as Health Evolution Partners, Alta Partners, DFJ Frontier, Arcturus Capital, DFJ Mercury, Funk Ventures, Phillip Capital, Gideon Hixon Fund, and Draper Associates. The use of human milk helps avoid serious side effects that can occur with premature infants if they use cow-based milk.

Arcturus 164

Arcturus Draper Monrovia Organization 164

socalTECH

JUNE 15, 2010

Prolacta is venture funded by Alta Ventures, DFJ Frontier, Arcturus Capital, DFJ Mercury, Funk Ventures, Phillip Capital, Gideon Hixon Fund, and Draper Associates L.P. The firm said it will commit a minimum amount of $25,000 annually to fund programs at Komen.

Arcturus 221

Arcturus Draper Monrovia Funding 221

socalTECH

JANUARY 12, 2011

The round was led by Prospector Equity Capital and Arcturus Capital, and also included the Pasadena Angels and Tech Coast Angels. Monrovia-based Ondax , a manufacturer of volume holographic grating filters and lasers, said Tuesday that it has officially closed its $2.2M, Series E funding round.

Tech Coast Angels 133

Tech Coast Angels Arcturus Pasadena Angels Monrovia 133

socalTECH

SEPTEMBER 23, 2011

Prolacta is venture backed by Alta Partners, Arcturus Capital, DFJ Frontier, DFJ Mercury Venture Partners, Draper Associates, Draper Richards, Funk Ventures, Gideon Hixon Fund, and Philip Capital. READ MORE>>.

Arcturus 166

Arcturus Draper Monrovia Capital 166

socalTECH

JANUARY 15, 2010

ONDAX is backed by Arcturus Capital, Prospector Equity Capital, and others. Christophe Moser, who is moving to Switzerland to become Professor of Engineering and Industrial Relations at Ecole Polytechnique Federale de Lausanne (EPFL). Moser is a native of Switzerland, and will remain as Chief Technology Officer at the firm.

Arcturus 124

Arcturus Chief Technology Officer Monrovia Equity 124

socalTECH

JUNE 19, 2009

Dr. Schuh was previously CEO and Director of AviaraDx, and also served at Arcturus Bioscience and Sequenom. The firm is headed by Antonius Schuh, who serves as founding chairman and CEO; the firm's CFO is Steve Zaniboni.

Arcturus 100

Arcturus San Diego Venture Capital Equity 100

socalTECH

SEPTEMBER 3, 2010

The firm is venture backed by Anthem Ventures, Arcturus Capital, Capital One, Capricorn Management, and GRP Partners. Painter is best known for being the founder and CEO of CarsDirect.com, but is also heavily involved in local startups such as SharesPost, and other firms through his BrightHouse business incubator.

Truecar 154

Truecar Pricing Tool Arcturus 154

socalTECH

SEPTEMBER 10, 2008

The firm said it has scored Series A funding from Zag, Anthem Venture Partners, Global Retail Partners, Capricorn, Capital One Auto Finance, ARcturus Capital, Scott Painter, and co-founder Tom Taira. According to TrueCar, it will provide information about new car pricing, using the actual price people have paid for cars.

Zag 133

Zag Truecar CarsDirect Arcturus 133

socalTECH

FEBRUARY 25, 2009

Zaniboni was also CFO for Arcturus Bioscience and Sequenom, XIFIN noted, adding that Taylor worked at IBM as a strategy executive prior to Acclerys. Most recently, XIFIN said, Zaniboni was CFO of AviaraDx, while Taylor served as vice president of marketing and corporate development for Acclerys Inc.

Arcturus 100

Arcturus Marketing IBM IBM 100

socalTECH

APRIL 27, 2009

TrueCar is venture backed by Zag, Anthem Venture Partners, Global Retail Partners, Capricorn, Capital One Auto Finance, and Arcturus Capital. The new service is free, and is based on automotive transactions within the last four weeks. READ MORE>>.

Truecar 100

Truecar Pricing Zag Sites 100

socalTECH

DECEMBER 1, 2010

Prolacta is venture backed by Alta Partners, DFJ Frontier, Arcturus Capital, DFJ Mercury, Funk Ventures, Phillip Capital, Gideon Hixon Fund, and Draper Associates L.P. READ MORE>>.

Arcturus 124

Arcturus Draper Monrovia Screening 124

socalTECH

JULY 7, 2009

Zag has previously received venture capital from such firms as Anthem Ventures, GRP Partners, the Tech Coast Angels, Capricorn Management, Capital One, and Arcturus Capital. The firm did not say what drove the growth, and did not provide any financial details on its sales or profitability. READ MORE>>.

Zag 100

Zag Sales CarsDirect Tech Coast Angels 100

socalTECH

APRIL 1, 2009

Zag is venture backed by Anthem Venture Partners, USAA, GRP Partners, Arcturus Capital, Callaway Cars and the Skoll Fund. Zag's technology differs from other similar programs in that it offers fully detailed pricing on exact options, rather than just feeding leads into a dealership's fleet or online department. READ MORE>>.

Zag 100

Zag Services Arcturus GRP Partners 100

socalTECH

JANUARY 22, 2009

Zag has previously received funding from Anthem Ventures, Arcturus Capital, Capital One, Capricorn Management, GRP Partners, and the Tech Coast Angels. The spokesperson for Zag said that the firm is "not quite ready to make that announcement" and would not releas details until later. READ MORE>>.

Zag 100

Zag Funding Tech Coast Angels Arcturus 100

socalTECH

JANUARY 22, 2009

Zag is venture backed by Anthem Ventures, Arcturus Capital, Capital One, Capricorn Management, GRP Partners, and the Tech Coast Angels, along with USAA. The spokesperson for Zag said that the firm is "not quite ready to make that announcement" and would not released details until later.

Zag 100

Zag Tech Coast Angels Arcturus GRP Partners 100

socalTECH

OCTOBER 24, 2008

The round was led by Rincon Venture Partners, and also included Arcturus Capital and Momentum Venture Management. Long Beach-based Digital Performance, which develops technology for online sales efforts in the after market automotive parts sector, is announcing Monday that it has raised $3.2M in a Series A funding round.

Arcturus 100

Arcturus Long Beach Resource Capital 100

socalTECH

OCTOBER 14, 2008

The firm is backed by Anthem Venture Partners, Capital One Auto Finance, GRP Partners, Arcturus Capital, Callaway Cars and the Skoll Fund. Zag develops software used for configuring and pricing new and used automobiles, which it provides on a white-label basis to affinity buying programs. READ MORE>>

Zag 100

Zag Arcturus GRP Partners Anthem 100

socalTECH

OCTOBER 6, 2008

Zag is headed by former CarsDirect CEO Scott Painter, and is venture backed by Anthem Venture Partners, Capital One Auto Finance, GRP Partners, Arcturus Capital, Callaway Cars and the Skoll Fund. Zag has now signed up 14 AAA motor clubs, and also provides its technology to Capital One Auto Finance, Overstock.com, and other sites.

Zag 100

Zag CarsDirect Arcturus GRP Partners 100

socalTECH

OCTOBER 21, 2013

San Diego-based Arcturus Therapeutics , a developer of RNAi technology, said it has raised $5M in a Series A funding round. According to Arcturus, the funding came from multiple private capital,, high net worth investors from Canada, Japan, and the United States. Names of those capital sources were not announced. READ MORE>>.

Arcturus 153

Arcturus San Diego .Net Venture Capital 153

socalTECH

JUNE 3, 2013

San Diego-based Arcturus Therapeutics , which is developing RNAi therapeutics to treat disease, said this morning that it has raised $1.3M Arcturus Therapeutics is headed by Joseph E. Arcturus Therapeutics is headed by Joseph E. arcturus therapeutics venture capital rnai lifescience biotech' in a seed fudning round.

Arcturus 138

Arcturus San Diego .Net Venture Capital 138

Xconomy

APRIL 17, 2020

The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol.

Equity 84

Equity Activity Marketing Company 84

Xconomy

JANUARY 3, 2019

As strains of bacteria evolve to fight back against common antibiotics, a slew of biotechnology companies are working to develop ways to combat these “superbugs.” San Diego’s Forge Therapeutics is among those targeting gram-negative bacteria, a type of bacteria that has a protective outer membrane that makes it especially resistant to drugs.

Develop 65

Develop Development San Diego Arcturus 65

Xconomy

FEBRUARY 9, 2018

The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. But the results, touted as positive, left more questions than answers.

Help 58

Help Develop Development Arcturus 58

Xconomy

MARCH 30, 2018

If the recent IPO activity seems to be on overdrive, it’s not your imagination. The number of companies filing to go public in the U.S. in the first quarter was up 44 percent compared to the same period a year ago, according to data compiled by consulting and accounting firm EY.

Activity 52

Activity Report Marketing Company 52